CMH Wealth Management LLC Has $1.96 Million Position in Amgen, Inc. (AMGN)

CMH Wealth Management LLC trimmed its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 9.1% during the 4th quarter, HoldingsChannel.com reports. The fund owned 11,083 shares of the medical research company’s stock after selling 1,115 shares during the quarter. Amgen makes up about 1.3% of CMH Wealth Management LLC’s investment portfolio, making the stock its 28th largest position. CMH Wealth Management LLC’s holdings in Amgen were worth $1,962,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Bremer Trust National Association boosted its position in Amgen by 7.4% during the fourth quarter. Bremer Trust National Association now owns 10,417 shares of the medical research company’s stock worth $1,811,000 after purchasing an additional 722 shares in the last quarter. Covenant Asset Management LLC boosted its position in Amgen by 18.1% during the fourth quarter. Covenant Asset Management LLC now owns 2,224 shares of the medical research company’s stock worth $387,000 after purchasing an additional 341 shares in the last quarter. Broadleaf Partners LLC purchased a new position in Amgen during the fourth quarter worth approximately $2,429,000. Appleton Partners Inc. MA boosted its position in Amgen by 8.9% during the fourth quarter. Appleton Partners Inc. MA now owns 18,038 shares of the medical research company’s stock worth $3,137,000 after purchasing an additional 1,478 shares in the last quarter. Finally, Indiana Trust & Investment Management CO boosted its position in Amgen by 62.1% during the fourth quarter. Indiana Trust & Investment Management CO now owns 3,994 shares of the medical research company’s stock worth $695,000 after purchasing an additional 1,530 shares in the last quarter. 78.95% of the stock is currently owned by hedge funds and other institutional investors.

In related news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $185.62, for a total value of $283,070.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders sold 4,575 shares of company stock valued at $818,361. Insiders own 0.19% of the company’s stock.

Shares of Amgen, Inc. (AMGN) opened at $183.55 on Friday. Amgen, Inc. has a fifty-two week low of $152.16 and a fifty-two week high of $201.23. The company has a debt-to-equity ratio of 1.35, a current ratio of 5.49 and a quick ratio of 5.17. The company has a market capitalization of $132,259.16, a P/E ratio of 14.59, a P/E/G ratio of 2.26 and a beta of 1.42.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.89 EPS for the quarter, missing the consensus estimate of $3.03 by ($0.14). Amgen had a net margin of 8.66% and a return on equity of 30.87%. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.84 billion. During the same period in the prior year, the business posted $2.89 EPS. Amgen’s revenue for the quarter was down 2.7% compared to the same quarter last year. research analysts forecast that Amgen, Inc. will post 13.21 EPS for the current year.

Amgen announced that its board has approved a stock repurchase plan on Wednesday, October 25th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical research company to reacquire shares of its stock through open market purchases. Shares repurchase plans are usually an indication that the company’s board believes its shares are undervalued.

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 8th. Investors of record on Thursday, February 15th will be issued a $1.32 dividend. This represents a $5.28 annualized dividend and a dividend yield of 2.88%. The ex-dividend date is Wednesday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $1.15. Amgen’s dividend payout ratio (DPR) is currently 205.45%.

A number of brokerages have issued reports on AMGN. Piper Jaffray Companies lowered their price target on Amgen from $194.00 to $190.00 and set an “overweight” rating on the stock in a research report on Friday, February 2nd. Atlantic Securities downgraded Amgen from an “overweight” rating to a “neutral” rating and set a $187.01 price target on the stock. in a research report on Monday, February 5th. BMO Capital Markets increased their price target on Amgen from $192.00 to $202.00 and gave the stock a “market perform” rating in a research report on Friday, February 2nd. Morgan Stanley lowered their price target on Amgen from $204.00 to $196.00 and set an “overweight” rating on the stock in a research report on Friday, February 2nd. Finally, Mizuho increased their price target on Amgen from $192.00 to $200.00 and gave the stock a “buy” rating in a research report on Monday, February 12th. Sixteen investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Amgen presently has a consensus rating of “Hold” and a consensus price target of $191.84.

TRADEMARK VIOLATION WARNING: “CMH Wealth Management LLC Has $1.96 Million Position in Amgen, Inc. (AMGN)” was first published by Week Herald and is the property of of Week Herald. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://weekherald.com/2018/02/18/cmh-wealth-management-llc-has-1-96-million-position-in-amgen-inc-amgn-2.html.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply